Form 4: Doximity Director Timothy Cabral Executes Stock Option and Sells Shares Under 10b5-1 Plan

Director Timothy Cabral exercised stock options and sold Doximity shares under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On February 3, 2025, Timothy Cabral, a director of Doximity, Inc., executed a stock option to acquire 20,000 shares of Class B Common Stock, which were then converted into Class A Common Stock.
• Cabral also sold 2,264 shares of Class A Common Stock at a weighted-average price of $56.8312, 16,536 shares at $57.6771, and 1,200 shares at $58.4033, all under a Rule 10b5-1 trading plan.
• Following these transactions, Cabral directly owns 26,360 shares of Class A Common Stock and 403,500 derivative securities (Stock Options) of Doximity.
• The sales were executed automatically pursuant to a Rule 10b5-1 trading plan adopted on February 15, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports insider trading activity under a pre-existing plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency to the market regarding the trading activities of company directors. It is common for executives to utilize 10b5-1 plans to manage their stock sales and avoid accusations of insider trading.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their insiders.
• The use of Rule 10b5-1 trading plans is a common strategy among corporate executives to sell shares in a compliant manner.
• Comparable companies such as Teladoc Health, GoodRx, and Amwell also have frequent Form 4 filings reflecting insider transactions.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the sale of shares by a director.
• The impact is likely minimal as the sales are conducted under a pre-arranged trading plan.

Key Dates